Gonadorelin
Synthetic gonadotropin-releasing hormone used diagnostically and therapeutically for reproductive hormone assessment and fertility.
What is Gonadorelin?
Gonadorelin is a synthetic version of the naturally occurring gonadotropin-releasing hormone (GnRH), a decapeptide produced by the hypothalamus. When administered in pulsatile fashion, it stimulates LH and FSH release from the pituitary, supporting natural testosterone and estrogen production. It is used diagnostically to assess pituitary function and therapeutically for hypogonadism and fertility.
What Gonadorelin Is Investigated For
Gonadorelin is the synthetic form of GnRH and has been investigated across three main contexts: pituitary function testing (FDA-approved historically as Factrel), pulsatile therapy for hypothalamic amenorrhea (historically approved as Lutrepulse), and off-label TRT-adjunct use to preserve testicular function and fertility in men on exogenous testosterone. The strongest evidence is for diagnostic pituitary testing — decades of well-characterized use — and the historical approval data for pulsatile pump therapy in hypothalamic amenorrhea. The contemporary TRT-adjunct use is the most discussed but has the thinnest evidence base: no randomized controlled trials specifically evaluate gonadorelin versus hCG or placebo in men on TRT for fertility and testicular preservation, and protocols are empirical. The honest caveats are significant: both Factrel and Lutrepulse are discontinued in the US, leaving no FDA-approved commercial product; the 2024 FDA 503A compounding review is narrowing legitimate access further; pulsatility is critical (continuous exposure paradoxically suppresses the axis via receptor desensitization, the same mechanism as leuprolide); and gonadorelin is prohibited by WADA under S2 at all times regardless of therapeutic intent.
History & Discovery
Gonadorelin is the synthetic form of gonadotropin-releasing hormone (GnRH), a 10-amino-acid hypothalamic peptide isolated and sequenced in the early 1970s by Andrew Schally's and Roger Guillemin's laboratories — work that contributed to their sharing the 1977 Nobel Prize in Physiology or Medicine. The peptide's sequence (pyroGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2) is identical to endogenous human GnRH and is the physiologic trigger at the top of the hypothalamic-pituitary-gonadal axis. In the US, synthetic gonadorelin was marketed as Factrel (Ayerst/Wyeth) for pituitary function testing, and as Lutrepulse (Ferring) delivered via programmable pulsatile pump for primary hypothalamic amenorrhea and related infertility indications. Both products are now discontinued in the United States, though their FDA approval history remains on the record. International veterinary use of gonadorelin for reproductive synchronization in cattle and other livestock remains extensive — which accounts for much of the peptide's published randomized trial literature. The contemporary story is the rise of off-label gonadorelin use as a TRT adjunct: men on exogenous testosterone began using small, pulsatile subcutaneous doses to preserve endogenous testicular function and fertility, substituting for hCG as hCG access tightened. This use was primarily supplied by US compounding pharmacies through the late 2010s and early 2020s. In 2024, the FDA flagged gonadorelin for safety review in the 503A compounding context, and regulatory signals indicate the pathway is closing. This has materially altered legitimate access for the TRT-adjunct user population.
How It Works
Gonadorelin is the master reproductive hormone. Given in pulses (like the body naturally does), it tells the pituitary gland to produce LH and FSH, which then stimulate testosterone or estrogen production. It keeps the entire hormone chain working naturally.
Gonadorelin (pyroGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2) binds the GnRH receptor (GnRHR) on pituitary gonadotrophs. Pulsatile activation (every 60-120 minutes) maintains receptor sensitivity and stimulates LH/FSH synthesis and secretion through Gq/PLC/IP3/DAG signaling. Pulse frequency determines LH vs FSH predominance. Continuous exposure causes receptor internalization and desensitization, paradoxically suppressing gonadotropins (the basis for GnRH agonist drugs like leuprolide).
Evidence Snapshot
Human Clinical Evidence
Extensive for diagnostic use. Moderate for therapeutic applications.
Animal / Preclinical
Comprehensive. GnRH biology is fundamental to reproductive endocrinology.
Mechanistic Rationale
Very strong. GnRH receptor signaling and HPG axis regulation are thoroughly characterized.
Research Gaps & Open Questions
What the current literature has not yet settled about Gonadorelin:
- 01Modern TRT-adjunct efficacy — despite widespread clinical use, randomized controlled trials specifically evaluating gonadorelin (vs. hCG, vs. placebo, vs. no adjunct) in men on TRT for fertility and testicular preservation are essentially absent.
- 02Optimal dosing for TRT adjunct — the 100–200 mcg SC two-to-three-times-weekly regimen is empirical; formal dose-ranging and pharmacokinetic-pharmacodynamic modeling in this specific population is missing.
- 03Long-term safety of chronic pulsatile gonadorelin — approved pump therapy was time-limited (months to achieve pregnancy); multi-year continuous TRT-adjunct exposure has no formal safety dataset.
- 04Comparative effectiveness vs. hCG — head-to-head trials comparing gonadorelin and hCG for testicular preservation, spermatogenesis, and symptomatic endpoints in TRT patients are lacking.
- 05Regulatory trajectory — the 2024 FDA 503A compounding review outcome will shape US access substantially, and users should expect rapid change in product availability and legitimacy of sources.
- 06Women's health applications beyond hypothalamic amenorrhea — contemporary use of pulsatile gonadorelin in broader infertility contexts is limited, and the discontinuation of Lutrepulse in the US has reduced research activity in this area.
Forms & Administration
SC or IV injection. Diagnostic: 100mcg single dose. Therapeutic: 50-100mcg SC 2-3 times daily or via pulsatile pump. Timing mimics natural GnRH pulsatility. All injectable peptides should only be administered under the guidance of a qualified healthcare provider. Never self-administer without clinician oversight.
Dosing & Protocols
The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.
Typical Range
The historical FDA-approved diagnostic dose (Factrel) was 100 mcg as a single subcutaneous or intravenous injection for pituitary function testing. The approved Lutrepulse protocol used 5 mcg per pulse every 90 minutes delivered via programmable pump for hypothalamic amenorrhea. Off-label TRT-adjunct protocols are markedly different: typical doses are 100–300 mcg per subcutaneous injection, with some clinicians using up to 500 mcg. For TRT adjunct, the intent is to replicate pulsatile LH stimulation without causing receptor desensitization.
Frequency
Diagnostic use: single dose. Approved Lutrepulse therapy: every 90 minutes for weeks to months via pump. Off-label TRT adjunct: the most commonly described cadence is 100–200 mcg two to three times weekly, though daily small-dose protocols (100 mcg once daily) and every-other-day schedules are also used. Pulsatility is important mechanistically — continuous gonadorelin exposure causes GnRH receptor downregulation (the mechanism leveraged by leuprolide and other GnRH agonists used to suppress the axis).
Timing Considerations
No specific timing requirements: can be administered at any time of day, with or without food, and is not tied to exercise timing. Consistency matters more than the specific clock — dose at roughly the same time each day (or same day each week, for weekly protocols) to keep exposure steady.
Cycle Length
Diagnostic use is single-dose. TRT-adjunct use is typically continuous alongside exogenous testosterone, with periodic reassessment of testicular volume, semen analysis where fertility is the goal, and LH/FSH response. Long-term continuous use of pulsatile gonadorelin at TRT-adjunct doses has not been rigorously studied.
Protocol Notes
The critical pharmacologic feature of gonadorelin is that route-and-frequency determine whether it stimulates or suppresses the axis. Pulsatile dosing at physiologic frequency (every 90–120 minutes in the Lutrepulse protocol) mimics endogenous GnRH and maintains LH/FSH secretion. Continuous exposure — either through long-acting analogs like leuprolide or through steady-state infusion — desensitizes the receptor and profoundly suppresses gonadotropins. TRT-adjunct SC protocols (100–200 mcg a few times weekly) are an empirical compromise: they produce transient LH surges without continuous exposure, but the dosing is well above the physiologic pulse amplitude and the frequency is lower than physiologic. Reconstitution is straightforward — most compounded gonadorelin comes lyophilized and is reconstituted in bacteriostatic water, then injected subcutaneously with an insulin-gauge syringe. Storage stability post-reconstitution is limited (typically 1–2 weeks refrigerated), which affects practical dosing schedules. The 2024 FDA compounding review is a live access issue. Users who previously obtained gonadorelin through 503A compounding pharmacies should expect that pathway to narrow or close in the US, and should not assume the drug will remain available through that channel.
Gonadorelin's US FDA approval history covers diagnostic and pulsatile-pump indications that are no longer actively marketed. TRT-adjunct use is off-label and is the subject of active regulatory review. Any use should be under the supervision of a qualified clinician who can verify product sourcing and monitor response.
Timeline of Effects
Onset
LH and FSH rise within 15–30 minutes of a gonadorelin injection, with peak gonadotropin response typically at 30–60 minutes. Testosterone response downstream in men follows over hours, depending on baseline Leydig cell function and whether testicular volume has already been affected by exogenous testosterone suppression. For TRT-adjunct users aiming to preserve testicular size and fertility, observable changes in testicular volume and semen parameters unfold over weeks to months.
Peak Effect
Acute pituitary response peaks within the hour. For TRT-adjunct use, meaningful preservation or restoration of testicular volume and spermatogenesis is typically assessed at 3–6 months of consistent dosing — on the timescale of full spermatogenic cycles.
After Discontinuation
Acute effects resolve within hours — gonadorelin's plasma half-life is approximately 2–4 minutes, making it one of the shorter-lived peptides used clinically. For TRT users who stop gonadorelin while continuing exogenous testosterone, testicular atrophy and spermatogenesis suppression return to the trajectory dictated by the ongoing testosterone use. For those discontinuing both gonadorelin and exogenous testosterone, recovery of the HPG axis follows the general post-TRT trajectory without clear evidence that prior gonadorelin use meaningfully accelerates or impairs recovery.
Monitoring & Measurement
Bloodwork & Labs
- •LH and FSH — the direct pituitary-output markers; the core endpoint for any gonadorelin protocol
- •Total and free testosterone
- •Estradiol via sensitive LC-MS/MS assay
- •SHBG
Functional & Performance Tests
- •Testicular volume via orchidometer — the simplest functional marker of preserved spermatogenesis during TRT-adjunct use
- •Semen analysis — if fertility preservation is a goal
When to Test
Baseline, 4 weeks, and 12 weeks. For acute response confirmation, draw LH 30 minutes post-injection on a representative dose.
Interpretation & Notes
In TRT-adjunct use, the goal is maintaining endogenous testosterone production and testicular volume while on exogenous testosterone. Gonadorelin is pulsatile by design — continuous dosing downregulates GnRH receptors and paradoxically suppresses the axis, so injection frequency matters at least as much as dose. An acute post-injection LH rise of at least 2x baseline at the 30-minute mark confirms the pituitary is responding to a given protocol; failure to rise usually means either receptor downregulation from too-frequent dosing or a degraded batch. Reproductive-hormone panels are widely available direct-to-consumer; testicular ultrasound and orchidometer measurement usually require a clinician.
Common Questions
Who Gonadorelin Is NOT For
- •Known hypersensitivity to gonadorelin or to compounded-preparation excipients — documented anaphylactoid reactions have occurred, including from repeated diagnostic use.
- •Hormone-sensitive malignancy — prostate cancer, certain breast cancers, and other hormone-responsive tumors where increased endogenous gonadotropin stimulation is contraindicated.
- •Pregnancy — not indicated during pregnancy; while short half-life limits direct exposure, the hormonal effects are inappropriate in the pregnant state.
- •Pituitary adenoma — gonadorelin stimulation testing in the presence of a known pituitary adenoma should be done by an endocrinologist with imaging and hormone-axis context, not empirically.
- •Active or prior pituitary apoplexy — stimulation testing in this context carries specific risks that require specialist evaluation.
- •Pediatric use outside of specific pediatric endocrinology indications (precocious puberty workup, cryptorchidism protocols) — empirical dosing in minors is not appropriate.
Drug & Supplement Interactions
Gonadorelin's short plasma half-life (minutes) limits sustained pharmacokinetic interactions, but its pharmacodynamic effects at the HPG axis create several meaningful interaction categories. The most important is with exogenous testosterone therapy — which is the primary off-label use case. Exogenous testosterone suppresses hypothalamic GnRH output; gonadorelin injection bypasses this by directly stimulating the pituitary. The interaction is the entire therapeutic rationale, but it means gonadorelin dosing should be calibrated against testosterone dose, frequency, and observed LH/FSH response, and managed by a clinician who understands both agents. Drugs that directly suppress GnRH or gonadotropin function — GnRH agonists and antagonists used in oncology and gynecology (leuprolide, goserelin, cetrorelix, degarelix), high-dose opioids, and high-dose glucocorticoids — oppose gonadorelin's intended effect and make dose interpretation unreliable. Anti-androgens, aromatase inhibitors, and selective estrogen receptor modulators interact downstream rather than at the pituitary and are generally compatible with gonadorelin therapy but should be managed by the prescribing clinician. Phenothiazines and dopamine antagonists can elevate prolactin and blunt gonadotropin response, complicating interpretation of diagnostic tests. Patients on any chronic medication should disclose gonadorelin use to their prescribing team.
Safety Profile
Common Side Effects
Cautions
- • Must be administered in pulsatile fashion for stimulatory effect
- • Continuous administration causes receptor desensitization (like leuprolide)
- • Timing and frequency of dosing are critical
What We Don't Know
Well-characterized safety profile for diagnostic use. Long-term therapeutic use data is more limited.
Legal Status
United States
Gonadorelin was FDA-approved as Factrel (diagnostic) and Lutrepulse (pulsatile therapy for hypothalamic amenorrhea). Both products have been discontinued in the US, though the approval history remains on record. There is currently no FDA-approved commercial gonadorelin product in the US. Off-label TRT-adjunct use has historically relied on state-licensed 503A compounding pharmacies; in 2024 the FDA signaled that gonadorelin is under safety review in the 503A compounding context, and access is narrowing. Research-chemical sales are not authorized for human use.
International
Gonadorelin and its veterinary counterparts are widely used internationally in livestock reproduction (cattle, sheep, horses), and the veterinary trial literature is extensive. Human prescribing varies by jurisdiction — some countries retain approved human-use products for diagnostic or fertility indications; others, like the US, have seen marketed products withdrawn over time. EMA and UK MHRA human-use availability is limited.
Sports & Competition
Gonadorelin is prohibited at all times (in and out of competition) by WADA under category S2 — peptide hormones and their releasing factors — which covers gonadotropin-releasing hormone and analogs. Athletes subject to WADA code, USADA, UKAD, or equivalent bodies must consider gonadorelin prohibited regardless of therapeutic intent.
Regulatory status changes over time. Verify current local rules with a qualified professional.
Myths & Misconceptions
Myth
Gonadorelin is a currently FDA-approved drug.
Reality
Gonadorelin was FDA-approved as Factrel and Lutrepulse historically, but both products are discontinued. There is no currently marketed FDA-approved gonadorelin product in the US. Off-label TRT-adjunct use has relied on compounded product, and the 2024 FDA review is narrowing that access pathway.
Myth
Gonadorelin and hCG do the same thing.
Reality
They act at different levels of the axis. hCG mimics LH and acts directly on Leydig cells to stimulate testosterone production, bypassing the pituitary. Gonadorelin stimulates the pituitary to release LH and FSH, preserving the entire HPG axis. The upstream mechanism is clinically meaningful when the goal is fertility preservation or natural LH pulsatility rather than just Leydig-cell stimulation.
Myth
Continuous gonadorelin dosing is fine and produces a stronger effect than pulsatile dosing.
Reality
The opposite is true. Continuous GnRH receptor exposure causes receptor internalization and desensitization — the mechanism leveraged by leuprolide and other GnRH agonists to suppress the HPG axis in prostate cancer and endometriosis. Gonadorelin only stimulates when delivered in pulses. Continuous infusion would suppress.
Myth
Gonadorelin prevents all TRT-related fertility loss.
Reality
Gonadorelin can help preserve testicular volume and spermatogenesis in many men on TRT, but it is not a guarantee. Individual response varies, semen parameters should be monitored when fertility is the goal, and men actively attempting conception during or shortly after TRT should work with a reproductive endocrinologist rather than rely on gonadorelin alone.
Myth
Gonadorelin is allowed for athletes because it's 'natural.'
Reality
Gonadorelin is explicitly prohibited by WADA under category S2 as a peptide hormone releasing factor, at all times, in and out of competition. Therapeutic intent does not exempt it. Athletes subject to WADA testing should treat gonadorelin as banned regardless of the underlying reason for use.
Published Research
32 studiesThe efficacy and safety of rhGH treatment combined with letrozole/GnRHa in adolescent boys
Effect of a GnRH injection on kisspeptin levels in girls with suspected precocious puberty: a randomized-controlled pilot study
Effect of 200 µg of gonadorelin at the first gonadotropin-releasing hormone of the Resynch-25 on ovarian dynamics and fertility in lactating Holstein cows
The safety of neoadjuvant hormonal treatment in infants with cryptorchidism
Nerve growth factor from seminal plasma origin (spβ-NGF) increases CL vascularization and level of mRNA expression of steroidogenic enzymes during the early stage of Corpus Luteum development in llamas
Equine chorionic gonadotropin increases fertility of grazing dairy cows that receive fixed-time artificial insemination in the early but not later postpartum period
A comparative study of the effects of intramuscular administration of gonadorelin, mating and intrauterine infusion of either raw seminal plasma or seminal plasma purified β-NGF on luteal development in llamas
Fertility of Angus cross beef heifers after GnRH treatment on day 23 and timing of insemination in 14-day CIDR protocol
Fertility of Holstein heifers after two doses of PGF2α in 5-day CO-Synch progesterone-based synchronization protocol
Estrous synchronization strategies to optimize beef heifer reproductive performance after reproductive tract scoring
Effects of gonadotropin-releasing hormone administration or a controlled internal drug-releasing insert after timed artificial insemination on pregnancy rates of dairy cows
Effect of different gonadorelin (GnRH) products used for the first or resynchronized timed artificial insemination on pregnancy rates in postpartum dairy cows
Effect of gonadorelin, lecirelin, and buserelin on LH surge, ovulation, and progesterone in cattle
Effects on normalized testicular atrophy index (TAIn) in cryptorchid infants treated with GnRHa pre and post-operative vs surgery alone: a prospective randomized trial and long-term follow-up on 62 cases
Endometrial expression of progesterone, estrogen, and oxytocin receptors and of 20α-hydroxysteroid dehydrogenase and cyclooxygenase II 2 and 5 days after ovulation in induced short and normal estrous cycles in dairy cows
Effect of increasing GnRH and PGF2α dose during Double-Ovsynch on ovulatory response, luteal regression, and fertility of lactating dairy cows
GnRH dose reduction decreases pituitary LH release and ovulatory response but does not affect corpus luteum (CL) development and function in llamas
Artificial insemination at 56 h after intravaginal progesterone device removal improved AI pregnancy rate in beef heifers synchronized with five-day CO-Synch + controlled internal drug release (CIDR) protocol
Effects of one versus two doses of prostaglandin F2alpha on AI pregnancy rates in a 5-day, progesterone-based, CO-Synch protocol in crossbred beef heifers
A multi-centre randomised phase III trial of Dexamethasone vs Dexamethasone and diethylstilbestrol in castration-resistant prostate cancer: immediate vs deferred Diethylstilbestrol
Equine chorionic gonadotropin and gonadotropin-releasing hormone enhance fertility in a norgestomet-based, timed artificial insemination protocol in suckled Nelore (Bos indicus) cows
Comparison of gonadorelin products in lactating dairy cows: efficacy based on induction of ovulation of an accessory follicle and circulating luteinizing hormone profiles
Pregnancy rates for grade 2 embryos following administration of synthetic GnRH at the time of transfer in embryo-recipient cattle
Treatment of cystic ovarian disease in dairy cows with gonadotrophin-releasing hormone: a field study
Unchanged response to stimulation of pituitary hormone release after serial UV irradiation in men
Prospective case control study to determine the effect of lovastatin on serum testosterone and cortisol concentrations in hyperlipidemic nephrotic patients with chronic renal failure
Bioequivalency comparison between two gonadotropin-releasing hormone products
Luteinizing hormone-releasing hormone (LHRH) and its analogs for contraception in women: a review
[Value of short-term use of a gonadorelin analog in an in vitro fertilization program]
[Treatment of advanced prostatic cancer with a gonadorelin agonist, dTrp6 LHRH. 41 cases]
[Comparative clinico-therapeutic study of gonadorelin and chorionic gonadotropin in boys with undescended testes]
Efficacy and safety of intravenous pulsatile gonadotropin-releasing hormone: Lutrepulse for injection
Quick Facts
- Class
- Gonadotropin-Releasing Hormone
- Tier
- A
- Evidence
- Strong
- Safety
- Well-Studied
- Updated
- Mar 2026
- Citations
- 32PubMed
Also known as
Tags
Peptide Families
Related Goals
Conditions Discussed
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.